1 Insulin resistance in thyroid disorders: association between anti-TPO and HOMA-IR

- 2 Hari Krishnamurthy^{2*} Thushani Siriwardhane¹, Karthik Krishna², Qi Song², Vasanth Jayaraman²,
- 3 Tianhao Wang², Kang Bei², John J. Rajasekaran²
- 4 Vibrant America LLC., San Carlos, CA, USA
- ² Vibrant Sciences LLC., San Carlos, CA, USA
- 6 Running title: Insulin resistance in thyroid disorders
- 7 Address correspondence to: Hari Krishnamurthy, Vibrant Sciences LLC., 1021 Howard Avenue,
- 8 Suite B, San Carlos, CA 94070, USA. Phone: 1-866-364-0963, Fax: 1-650-508-8262. E-mail:
- 9 hari@vibrantsci.com
- 10 Thushani Siriwardhane: thushanis@vibrant-america.com
- 11 Vasanth Jayaraman: vasanth.jayaraman@vibrantsci.com
- 12 Karthik Krishna: karthik@vibrantsci.com
- 13 Qi Song: qsong@vibrant-america.com
- 14 Tianhao Wang: tianhao.wang@vibrantsci.com
- 15 Kang Bei: kang@vibrantsci.com
- 16 John J. Rajasekaran: jjrajasekaran@vibrantsci.com
- 17

18 ABSTRACT

19 The association of thyroid disease and diabetes has been classically described. However, the comorbidity of thyroid disparities and insulin resistance is not frequently assessed, especially the 20 sequence of the occurrence of these markers. We performed a retrospective analysis to evaluate 21 22 the association between thyroid disease and diabetes markers. We further investigated the sequence of occurrence of thyroid and diabetes markers to identify any predictive capabilities of 23 24 these markers. We evaluated 32787 subjects who were classified based on their serum thyroid hormones and autoantibody levels. Our general prevalence results showed that HOMA-IR was 25 elevated in overt hypothyroid subjects (43.7%) and overt hyperthyroid subjects (42.2%). HbA1C 26 was elevated in subclinical hypothyroid subjects (19.2%), overt hypothyroid subjects (22.3%) 27 and overt hyperthyroid subjects (21.2%). Glucose was significantly elevated in subclinical 28 hypothyroid subjects (24.2%) and overt hyperthyroid subjects (31.0%). Insulin was only 29

- 30 significantly elevated in overt hypothyroid subjects (15.1%). Interestingly, we found that 70.3%
- of subjects who had their HOMA-IR score escalated from negative (HOMA-IR<2.7) to positive
- 32 (HOMA-IR>2.7) during their multiple visits had anti-TPO 369 (\pm 242) days prior to the onset of
- this change. Our comprehensive study provided evidence that the presence of anti-TPO may
- 34 suggest a predictive role in developing insulin resistance later in life.
- 35 Key Words: HOMA-IR, Hyperthyroidism, Hypothyroidism, Anti-TPO, Insulin Resistance
- 36 Strengths and limitations of the study:
- The strength of our study is the large population size including a larger set of markers
 from both thyroid disease and diabetes.
- The limitation in our study is the distorted male and female ratio.
- 40

41 INTRODUCTION

Thyroid hormones exert a fine balance in glucose metabolism, acting as both an insulin agonist 42 and an antagonist in different organs. An imbalance, a deficit, or an excess of thyroid hormones 43 44 could cause disequilibria leading to different disorders, especially in carbohydrate metabolism and insulin resistance.¹ Thyroid diseases and diabetes are the two most common endocrine 45 disorders encountered in clinical practice. Thyroid disease is mainly classified into 46 hypothyroidism and hyperthyroidism. Elevated levels of thyroid hormones are seen in 47 hyperthyroidism while low levels of thyroid hormones are prevalent in hypothyroidism. Insulin 48 49 resistance is a condition either caused by defects in insulin production by pancreatic β -cells or defects in effectively employing its function in target cells leading to diabetes. The prevalence of 50 51 thyroid disease in patients with diabetes is significantly increased than that in the general population. A study conducted by Perros et al. demonstrated a prevalence of 31.4% of thyroid 52 disease in type 1 female diabetes and 6.9% in type 2 male diabetes.² In addition to diabetes, 53 studies have indicated a possible relationship between thyroid status and insulin sensitivity. 54 55 Though the results of the studies on the effect of thyroid dysfunction on insulin resistance are 56 controversial, many studies have shown that hyperthyroidism may cause impaired glucose 57 tolerance leading to hepatic insulin resistance while hypothyroidism may cause insulin resistance in peripheral tissues.³ Additionally, insulin resistance and autoimmune thyroid disease have 58 shown to mutually influence each other. Studies have reported positive connections between 59 thyroid autoantibodies and insulin resistance.⁴⁻⁶ Most of these studies have utilized the 60 Homeostatic model assessment (HOMA) method to evaluate the insulin resistance of individuals. 61

62 HOMA-IR (HOMA-insulin resistance) is a mathematical model for assessing β-cell function and 63 insulin resistance from fasting glucose and insulin. The HOMA-IR score is determined from 64 glucose and insulin levels in blood in baseline/fasting conditions. In HOMA-IR score, the plasma 65 glucose and insulin concentrations were reflecting the hepatic and peripheral glucose efflux and

66 uptake, while decreases in β-cell function were modeled by changing the β-cell response to 67 plasma glucose concentrations.^{7, 8} The HOMA-IR has proven to be a robust tool for the surrogate

68 assessment of insulin resistance.

69 Previous studies have suggested a close correlation between insulin resistance and thyroid 70 autoantibodies. However, studies to evaluate the sequence of occurrence of each marker have not been performed. Anti-TPO has been shown to precede years before the onset of many diseases, 71 such as autoimmune thyroid disease, connective tissue disorders, etc.⁹⁻¹¹ In the present study, we 72 first investigated the prevalence of diabetes markers in thyroid disease individuals and then 73 74 explored the sequential occurrence of thyroid autoantibodies, anti-TPO, and anti-Tg in relation to 75 HOMA-IR score changes. Understanding the sequential occurrence of these biomarkers will not only help to recognize the disease pathogenesis but also may help for disease prognosis to 76 identify at-risk individuals. 77

78 MATERIALS AND METHODS

79 Study Design and Population

A total of 32787 subjects who had suspected thyroid disease or related conditions were tested for 80 81 thyroid panel and diabetes markers at the Vibrant America Clinical Laboratory by the standard thyroid panel and the diabetes panel between January 2015 and June 2019. Subjects were 82 characterized based on their serum thyroid markers as subclinical hypothyroidism, overt 83 hypothyroidism, subclinical hyperthyroidism, overt hypothyroidism, and controls (thyroid 84 hormones in range). The clinical information on the majority of these patients was provided by 85 physicians as ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical 86 Modification) codes. The percentage distribution of the top 20 ICD-10-CM codes reported is 87 listed in table S1. This cohort was subdivided into single visit subjects (only visited once 88 between January 2015 and June 2019) and multiple visit subjects (three or more visits between 89 90 January 2015 and June 2019) for different analysis purposes.

91 Thyroid Panel

TSH, FT4, anti-TPO, and anti-Tg were measured using the commercial Roche e601 analyzer 92 93 (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's recommendations. 94 All reagents were purchased from Roche Diagnostics (Indianapolis, IN, USA). Human serum specimens were used on Elecsys immunoassay analyzers. Elecsys TSH assay was based on 95 specific TSH monoclonal antibodies specifically directed against human. The antibodies labeled 96 97 with a ruthenium complex consist of a chimeric construct from human- and mouse-specific components. As a result, interfering effects due to HAMA (human anti-mouse antibodies) were 98 largely eliminated. The Elecsys FT4 test employed a specific anti-T4 antibody labeled with a 99 ruthenium complex to determine the free thyroxine. The Elecsys T3 assay employs polyclonal 100 antibodies specifically directed against T3. Endogenous T3, released by the action of 8-anilino-1-101 102 naphthalene sulfonic acid (ANS), competes with the added biotinylated T3-derivative for the

binding sites on the antibodies labeled with the ruthenium complex. In the Elecsys FT3 test the 103 determination of free triiodothyronine is made with the aid of a specific anti-T3 antibody labeled 104 with a ruthenium complex. The Elecsys T4 assay employs an antibody specifically directed 105 against T4. Endogenous T4, released by the action of 8-anilino-1-naphthalene sulfonic acid 106 107 (ANS), competes with the added biotinylated T4-derivative for the binding sites on the antibodies labeled with the ruthenium complex. RT3 was measured using LC-MS on the Xevo 108 TQ-XS mass spectrometer. Elecsys anti-TPO assay employed recombinant antigens and 109 polyclonal anti-TPO antibodies whereas Elecsys anti-Tg assay employed monoclonal human 110 anti-Tg antibodies. 111

112 **Reference Ranges for Thyroid Markers**

113 Thyroid hormone reference ranges are subject to the lab where the test is performed. In this 114 study, we followed the reference ranges that majority of the labs used. The reference range of 115 hormones and autoantibody levels in a healthy control used in this study are shown in table 1. 116 Subclinical hypothyroidism, subclinical hyperthyroidism, overt hypothyroidism and overt

117 hyperthyroidism were attributed using these ranges.

118 The categorization of thyroid disease status by evaluating TSH and FT4 levels used in this study 119 is shown in table 2.

120

121 Diabetes Panel

The Diabetes panel consist of HbA1C, ADIP, Glucose, Glymark, GSP, Insulin. The HbA1c 122 123 determination was based on the turbidimetric inhibition immunoassay (TINIA) for hemolyzed whole blood. The glucose assay was based on the enzymatic reference method with hexokinase. 124 Hexokinase catalyzed the phosphorylation of glucose to glucose-6-phosphate by ATP. Glucose-125 6-phosphate dehydrogenase oxidized glucose-6-phosphate in the presence of NADP to 126 gluconate-6-phosphate. No other carbohydrate was oxidized. The rate of NADPH formation 127 during the reaction was directly proportional to the glucose concentration and was measured 128 photometrically. The diazyme insulin assay was used to determine insulin in serum samples. 129 130 Latex particles coated with antibody specific to human insulin was used to react with insulin 131 present in the sample. Immunoturbidimetry was using Beckman Counter AU series analyzer (Beckman Coulter, Inc., Georgia, USA) was used to measure the turbidity at 600nm primary and 132 800 nm secondary. The Glycated serum protein assay used proteinase K to digest GSP into low 133 134 molecular weight glycated protein fragments and used diazyme's specific fructosaminase. The colorimetric product was measured at 546-600 nm. ADIP assay was based on adiponectin and 135 136 anti-adiponectin coated latex complexation. The turbidity of the antibody-antigen complex was measured at 570 nm via Roche Cobas 6000 c501 (Roche Diagnostics, Indiana, USA). 137

138 HOMA-IR Calculation

- 139 HOMA-IR was calculated as:
- 140 HOMA-IR = [Fasting Plasma Glucose (mg/dl) × Fasting Insulin(μ U/ml)]/405

141 Patient and Public Involvement

This study does not include any patient or public involvement and is based on retrospective analysis of de-identified laboratory data. IRB exemption (work order #1-1098539-1) was determined by the Western Institutional Review Board (WIRB) for Vibrant America Biorepository to use de-linked and de-identified remnant human specimen and medical data for research purposes.

147 Statistical Analysis

- 148 The data were analyzed using Java for Windows version 1.8.161 and R for Windows version
- 149 3.5.0. Data were expressed as mean $\Box \pm \Box$ standard deviation (SD). The association between PSA
- and autoimmune markers and controls were tested using nonparametric chi-square test with 95%
- 151 confidential interval. P value < 0.05 was considered statistically significant.

152 **RESULTS**

153 **Patient Clinical Characteristics**

A total of 32787 subjects who ordered the thyroid panel and the diabetes panel were included in this retrospective study. Table 3 shows the demographics of thyroid positive subjects (different thyroid diseases based on their serum thyroid hormone levels) and negative controls in this study.

158 **Prevalence of Diabetes markers in thyroid disease**

159 To evaluate the general prevalence of diabetes markers in thyroid disease subjects, we first assessed single visit subjects who had tested for both thyroid disease and diabetes markers 160 (HOMA-IR, HbA1C, ADIP, Glucose, Glymark, GSP, Insulin). Figure 1 shows the diabetes 161 markers significantly elevated in different thyroid disease subjects grouped as subclinical 162 hypothyroidism, overt hypothyroidism, subclinical hyperthyroidism, overt hyperthyroidism 163 164 based on their serum TSH and FT4 levels. HOMA-IR was elevated in overt hypothyroid subjects (171/391, 43.7%) and overt hyperthyroid subjects (129/306, 42.2%) compared to its controls, the 165 thyroid negative group (10763/28896, 37.2%). HbA1C was elevated in subclinical hypothyroid 166 167 subjects (639/3325, 19.2%), overt hypothyroid subjects (137/614, 22.3%) and overt hyperthyroid subjects (101/476, 21.2%) compared to its controls (7237/44829, 16.1%). Glucose was 168 significantly elevated in subclinical hypothyroid subjects (579/2394, 24.2%) and overt 169 170 hyperthyroid subjects (106/342, 31.0%) compared to its control (6984/31803, 22%). Insulin was only significantly elevated in overt hypothyroid subjects (72/478, 15.1%) compared to its control 171 172 (4022/35197, 11.4%). Subclinical hyperthyroidism did not a show significant relationship with any of the diabetes markers. 173

174 Next, we tested the prevalence of these diabetes markers in antibodies (Anti TPO, Anti Tg) and

- individual thyroid hormones (TSH, FT4, FT3, RT3, T3, T4). Table 4 provides the prevalence of
- 176 diabetes markers in subjects with elevated thyroid autoantibodies. HOMA-IR score was elevated
- 177 in subjects seropositive to anti-TPO and anti-Tg. High insulin levels were seen in subjects with
- 178 anti-TPO positivity. The prevalence of diabetes markers in subjects with elevated/reduced levels
- 179 of individual thyroid hormones are listed in table S2.
- 180

181 Early detection of anti-TPO antibodies predicted HOMA-IR score change

182 To evaluate the direction of disease correlation between diabetes and thyroid disease we extracted subjects who had multiple visits during the time of the study (January 2015 to June 183 2019). First, a sub cohort who had HOMA-IR<2.7 (negative) in their initial test but increased 184 185 over time (HOMA-IR>2.7-positive) during their subsequent visits were selected to analyze their clinical profiles to identify any predictive markers for insulin resistance. A total of 155 subjects 186 was included in this group. As shown in figure 2, 109/155 (70.3%) had anti-TPO 369 (± 242) 187 days (ranging from 55 days to 1229 days) prior to the onset of HOMA-IR change from negative 188 to positive. It was significantly different from control group which had 46/155 (29.7%) subjects 189 190 with either no anti-TPO presence or anti-TPO on or after the negative HOMA-IR change to 191 positivity. Anti-Tg (56/155, 36.1%) or any thyroid disease profile (subclinical hypothyroidism-8/155, 5.2%, overt hypothyroidism- 2/155, 1.3%, subclinical hyperthyroidism-12/155, 7.7%, 192 overt hypothyroidism- 2/155, 1.3%) did not show this predictive behavior. Next, we analyzed the 193 194 early occurrence of HOMA-IR positivity in subjects who have converted from seronegative to seropositive for anti-TPO, anti-Tg and thyroid profiles to identify whether high HOMA-IR 195 scores could predict thyroid disease. Of 206 subjects, 36 (17.5%) had HOMA-IR positivity 196 before the onset of anti-TPO seropositivity. Moreover, 13/70 (18.6%) subjects only had HOMA-197 198 IR positivity before the onset of thyroid disease and 16/64 (25.0%) had HOMA-IR change prior 199 to the onset of anti-Tg negativity. These data did not show any significant relationship with HOMA-IR positivity occurring ahead of either anti-TPO, anti-Tg or thyroid disease. 200

201

202 **DISCUSSION**

Our study is the first in the literature evaluating the sequence of markers occurring in thyroid disease and insulin resistance comorbidity. Patients with thyroid disparities are known to have glucose and insulin metabolism disorders, however, none of the studies have elucidated the disease marker sequence. The direction of disease correlation is important for effective follow-up testing and treatment strategies for at-risk subjects.

To understand the general prevalence, we first evaluated the association between thyroid disease and diabetes markers in single visit subjects. We evaluated thyroid disease profiles categorized based on their serum TSH and FT4 levels. We found that both overt hypothyroidism and overt

hyperthyroidism had elevated levels of HOMA-IR. HbA1C was elevated in subclinical 211 hypothyroidism, overt hypothyroidism and overt hyperthyroidism. Glucose was elevated in both 212 213 subclinical hypothyroidism and overt hyperthyroidism and insulin is only elevated in overt hypothyroidism. Clinical hyperthyroidism is associated with abnormal glucose tolerance and 214 insulin resistance.¹² Specifically, overt hyperthyroidism has increased demand for insulin which 215 is often due to accelerated metabolism, tissue resistance to insulin, and elevated insulin 216 degradation.³ Many theories have established to explain the peripheral insulin resistance in 217 hyperthyroidism. Some studies show that increased secretion of adiponectin such as interleukin-218 6, and TNF- α in hyperthyroid patients may be related to the development of insulin resistance.¹⁴ 219 220 Another mechanism by which thyroid hormones increase hepatic glucose production is through the increased expression of GLUT2 transporter on hepatic plasma membrane which was found to 221 be twice as high in hyperthyroid patients compared to hypothyroid patients.¹ There are 222 comparatively lesser human studies conducted to evaluate the association between 223 224 hypothyroidism and insulin resistance. In hypothyroidism, it is speculated that decreased intestinal glucose absorption rate and decreased adrenergic activity may lead to a reduction in 225 glycogenolysis in the liver and muscles and gluconeogenesis that could further decrease the 226 baseline insulin secretion.^{12, 15} Our results indicated a significant prevalence of increased 227 HOMA-IR scores in hypothyroid subjects indicating a possible insulin resistance. Similar results 228 229 were also seen by other groups where they found hypothyroidism induced a decrease in the insulin-mediated glucose disposal that reverted upon treatment.¹⁶⁻¹⁸ 230

Autoimmune thyroid disease and insulin resistance are two chronic inflammatory diseases. 231 Hence, we evaluated the relationship between subjects that were seropositive for thyroid 232 autoantibodies and insulin resistance. Our results showed that subjects with thyroid antibodies, 233 anti-TPO and anti-Tg had significantly elevated HOMA-IR scores compared to their respective 234 control groups. Moreover, seropositive subjects for anti-TPO had elevated insulin levels 235 compared to seronegative subjects. Studies have shown a connection between anti-TPO titer, the 236 secretory function of monocytes, lymphocytes and pro-inflammatory cytokines such as $TNF-\alpha$ 237 and IL-6.¹⁹ These monocytes, lymphocytes and their secretary cytokines TNF- α and IL-6 are also 238 responsible for developing insulin resistance.²⁰ Our results were consistent with Tina Mazaheri et 239 al. where they found significantly high insulin levels in subjects with anti TPO antibodies more 240 than 1000 IU/ml.²¹ However, their HOMA-IR score did not show any significant difference. 241

It has long been a topic of controversy about the direction of the effect of insulin resistance and 242 autoimmune thyroid disease on each other. To our knowledge, none of the studies have evaluated 243 the direction of these two comorbid diseases, diabetes and thyroid disease. To assess the 244 sequence of occurrence of these disease markers, we evaluated the predictive characteristics of 245 anti-TPO, anti Tg, and thyroid disease in insulin resistance and vice versa. Interestingly, we 246 found that 70.3% subjects had anti-TPO prior to the HOMA-IR change from negative to positive, 247 248 indicating a possible predictive role of anti-TPO in insulin resistance. None of the thyroid 249 disease profiles (15.5%) nor anti-Tg (36.1%) preceded the HOMA-IR score change, indicating

that thyroid disease profiles or anti-Tg does not contain any significant predictability on insulin resistance. However, the opposite direction, the appearance of insulin resistance, in terms of high HOMA-IR scores, appearing before anti-TPO positivity, anti-Tg positivity or any thyroid disease positivity did not provide any significant results, eliminating the hypothesis of the occurrence of insulin resistance before anti-TPO, anti-Tg or thyroid disease seropositivity.

In this study, we mainly examined the effect of direction of comorbid diseases, thyroid disease 255 and insulin resistance. The primary strength of our study is the large population size including a 256 larger set of markers from both thyroid disease and diabetes. However, a limitation in our study 257 258 is the distorted male and female ratio. A study with similar male and female ratio with all-259 inclusive clinical characteristics such as thyroid treatments, female menopausal status, etc. would be required to extrapolate the results to eventually achieve a generalized outcome. In conclusion, 260 we showcased that thyroid autoantibody, anti-TPO precedes the changes in insulin resistance in 261 terms of HOMA-IR score changes from negative to positive, thus anti-TPO could eventually be 262

used as a predictive marker for disease stratification.

264 **Consent for Publication**

265 N/A

266 Availability of data and material

The raw data supporting the conclusions of this manuscript will be made available by the corresponding author on reasonable request.

269 **Competing interests**

The authors have read the journal's policy and the authors of this manuscript have the following competing interests: TS and QS are paid employees of Vibrant America LLC. KK, VJ, TW, KB, HK, JJR, are paid employees of Vibrant Sciences LLC. Vibrant Sciences or Vibrant America could benefit from increased testing based on the results. There are no patents, products in development, or marketed products to declare.

275 Funding

Vibrant America provided funding for this study in the form of salaries for authors [TS, QS, KK,

- VJ, TW, KB, HK, JJR]. The funders had no role in study design, data collection and analysis,
- 278 decision to publish, or preparation of the manuscript.

279

280 Author contributions

281 Conception and study design: HK, JR, VJ. Performing experiments: KK, TW. Analysis and

interpretation: TS, KB, QS, HK. Manuscript preparation: TS, HK. All authors read and approved

the final manuscript.

284 Acknowledgement

285 We acknowledge Vibrant America LLC for supporting this research.

286 Ethics approval and consent to participate

The study was conducted under the ethical principles that have their origins in the Declaration of Helsinki. This is a retrospective study conducted from remnant samples of individuals that visited Vibrant Clinical Lab for routine tests. The IRB (WCG IRB (Western Institutional Review Board) (#1-1098539-1)) exemption enabled us to use the de-identified laboratory data for the retrospective analysis. The data and materials in this manuscript have not been published elsewhere and are not under consideration by another journal.

293

294 **REFERENCES**

295

- 2961.Brenta G. Why Can Insulin Resistance Be a Natural Consequence of Thyroid
- 297 Dysfunction? *Journal of Thyroid Research*. 2011; 2011.
- Perros P, McCrimmon RJ, Shaw G and Frier BM. Frequency of thyroid dysfunction in
 diabetic patients: value of annual screening. *Diabet Med.* 1995; 12: 622-7.
- 300 3. Gierach M, Gierach J and Junik R. Insulin resistance and thyroid disorders. *Endokrynol*301 *Pol*. 2014; 65: 70-6.
- Barker JM, Yu J, Yu L, et al. Autoantibody "subspecificity" in type 1 diabetes: risk for
 organ-specific autoimmunity clusters in distinct groups. *Diabetes Care*. 2005; 28: 850-5.
- Kordonouri O, Maguire AM, Knip M, et al. Other complications and associated
 conditions with diabetes in children and adolescents. *Pediatr Diabetes*. 2009; 10 Suppl 12: 20410.
- Holl RW, Bohm B, Loos U, Grabert M, Heinze E and Homoki J. Thyroid autoimmunity
 in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type. *Horm Res.* 1999; 52: 113-8.
- Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB and Supiano MA. Limitation of
- 311 the Homeostasis Model Assessment to Predict Insulin Resistance and β -Cell Dysfunction in
- Older People. *The Journal of Clinical Endocrinology & Metabolism.* 2006; 91: 629-34.
- 8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC.
- Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma
- glucose and insulin concentrations in man. *Diabetologia*. 1985; 28: 412-9.

- 9. Hutfless S, Matos P, Talor MV, Caturegli P and Rose NR. Significance of prediagnostic
- thyroid antibodies in women with autoimmune thyroid disease. *J Clin Endocrinol Metab*. 2011;
 96: E1466-71.
- Siriwardhane T, Krishna K, Ranganathan V, et al. Significance of Anti-TPO as an Early
 Predictive Marker in Thyroid Disease. *Autoimmune Diseases*. 2019; 2019: 6.
- 11. Siriwardhane T, Krishna K, Ranganathan V, et al. Exploring Systemic Autoimmunity in
- Thyroid Disease Subjects. *Journal of Immunology Research*. 2018; 2018: 7.
- 12. Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol*. 2009; 160: 785-90.
- 13. Donckier J. Endocrine diseases and diabetes. In: Pickup J and Williams G, (eds.).
- 326 *Textbook of diabetes*. Blackwell Publishing, 2003, p. 27.1–.15.
- Mitrou P, Boutati E, Lambadiari V, et al. Insulin resistance in hyperthyroidism: the role
 of IL6 and TNFα. 2010; 162: 121.
- 15. Dimitriadis G, Mitrou P, Lambadiari V, et al. Insulin Action in Adipose Tissue and
- Muscle in Hypothyroidism. *The Journal of Clinical Endocrinology & Metabolism*. 2006; 91:
- **4930-7**.
- 16. ROCHON C, TAUVERON I, DEJAX C, et al. Response of glucose disposal to
- hyperinsulinaemia in human hypothyroidism and hyperthyroidism. *Clinical Science*. 2003; 104:
 7-15.
- 17. Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M and Zamrazil V. Insulin sensitivity
- and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement
- therapy. Clin Chem Lab Med. 2005; 43: 715-20.
- 138 18. Handisurya A, Pacini G, Tura A, Gessl A and Kautzky-Willer A. Effects of T4
- replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). *Clinical Endocrinology*. 2008; 69: 963-9.
- 19. Nielsen CH, Brix TH, Leslie RG and Hegedus L. A role for autoantibodies in
- enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. *Clin*
- 343 *Immunol*. 2009; 133: 218-27.
- 20. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA and Sowers JR. Skeletal
- muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. *Am J*
- 346 *Physiol Regul Integr Comp Physiol*. 2008; 294: R673-80.
- 347 21. Mazaheri T, Sharifi F and Kamali K. Insulin resistance in hypothyroid patients under
- Levothyroxine therapy: a comparison between those with and without thyroid autoimmunity. J
- 349 *Diabetes Metab Disord*. 2014; 13: 103.
- 350



Figure 1. Prevalence of diabetes markers in subjects with different thyroid disease profiles compared to their controls (thyroid disease negative). Diabetes markers significantly elevated/reduced are only shown.



Figure 2. The prevalence of different thyroid diseases, anti-TPO, and anti-Tg prior to the onset of HOMA-IR elevation compared to their respective control groups. Thyroid control group consists of subjects who had thyroid disease-parallel, thyroid disease-following, and no thyroid disease to the onset of HOMA elevation. Anti-TPO control group consists of subjects who had anti-TPO-parallel, anti-TPO -following, and no anti-TPO to the onset of HOMA elevation. Anti-Tg control group consists of subjects who had anti-Tg-parallel, anti-Tg-following, and no anti-Tg to the onset of HOMA elevation.

Table 1. Reference ranges for thyroid markers studied

Reference Range
0.3-4.2 mIU/L
0.9-1.7 ng/dL
<9.0 IU/mL
<4.0 IU/mL

Table 2. Thyroid disease categorization

Disease Condition	TSH	FT4
Subclinical hypothyroidism	> 4.2 mIU/L	0.9-1.7 ng/dL
Subclinical hyperthyroidism	< 0.3 mIU/L	0.9-1.7 ng/dL
Overt hypothyroidism	> 4.2 mIU/L	< 0.9 ng/dL
Overt hyperthyroidism	< 0.3 mIU/L	> 1.7 ng/dL
Thyroid Disease negative	0.3-4.2 mIU/L	0.9-1.7 ng/dL

	Subclinical	Overt	Subclinical	Overt	Thyroid-
	Hypothyroidism	Hypothyroidism	Hyperthyroidism	Hyperthyroidism	(Control)
	3455/52662	637/52662	1626/52662	494/52662	46450/52662
Ν	(6.6%)	(1.2%)	(3.1%)	(0.9%)	(88.2)
Gender	1258M/2197F	134M/503F	168M/1458F	72M/422F	16812M/29638F
Age	50.0M/48.2F	53.4M/51.3F	55.8M/52.5F	52.9M/53.0F	47.1M/45.6F

Table 3. Demographics of subjects with different thyroid disease profiles.

Table 4. Prevalence of diabetes markers in subjects with elevated thyroid autoantibodies.

	Anti TPO+	Anti TPO-	P Value	Anti Tg+	Anti Tg-	P Value
HOMA-			<0.0001			<0.0001
IR	45.5%	37.5%		41.1%	37%	
Positive	(1869/4104)	(11015/29387)		(1747/4255)	(8285/22364)	
High	16.3%	15.4%	0.0930	14%	14.7%	0.2100
HbA1C	(990/6076)	(6502/42088)		(872/6210)	(4701/32057)	
Low			0.0028			< 0.0001
ADIP	2.2% (94/4184)	3.1% (918/29592)		1.7% (74/4391)	3% (671/22699)	
High	22.1%	22%	0.9022	19.8%	21.5%	0.0093
Glucose	(1001/4525)	(7097/32218)		(908/4595)	(5186/24139)	
Low			0.6659		1.9%	0.7262
Glucose	1.7% (75/4525)	1.8% (567/32218)		1.8% (84/4595)	(463/24139)	
Low	10.3%	10.1%	0.7564	8.6%	10.1%	0.0132
Glymark	(314/3058)	(2250/22345)		(259/2998)	(1509/14881)	
	10.7%	10.7%	1.0000	11.3%	11.4%	0.8507
GSP	(438/4104)	(3159/29601)		(476/4215)	(2540/22266)	
High	14.1%	11.5%	0.0006	11.2%	11.1%	0.7735
Insulin	(266/1888)	(4490/39169)		(588/5238)	(2990/26991)	
Low	2.9%		0.8936	2.8%	2.8%	0.9916
Insulin	(144/5005)	2.8% (986/34815)		(149/5238)	(764/26991)	